{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:38:59Z","timestamp":1787989139227,"version":"build-2784847793"},"reference-count":157,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","surveyophthalmol.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Survey of Ophthalmology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.survophthal.2025.01.010","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T11:23:39Z","timestamp":1737545019000},"page":"704-712","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["An update on ocular effects of antidiabetic medications"],"prefix":"10.1016","volume":"70","author":[{"given":"Elham","family":"Sadeghi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elham","family":"Rahmanipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Valsecchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saloni","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Vittoria","family":"Cicinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3488-9680","authenticated-orcid":false,"given":"Jay","family":"Chhablani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.survophthal.2025.01.010_bib1","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/6620661","article-title":"Evaluation of the effect of garlic tablet as a complementary treatment for patients with diabetic retinopathy","volume":"2022","author":"Afarid","year":"2022","journal-title":"J Diabetes Res"},{"key":"10.1016\/j.survophthal.2025.01.010_bib2","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1001\/jamaophthalmol.2023.5478","article-title":"Metformin use and age-related macular degeneration in patients without diabetes","volume":"142","author":"Aggarwal","year":"2024","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.survophthal.2025.01.010_bib3","article-title":"From sequence analysis of DPP-4 to molecular docking based searching of its inhibitors","author":"Alsamghan","year":"2020","journal-title":"Bioinformation"},{"key":"10.1016\/j.survophthal.2025.01.010_bib4","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1001\/archophthalmol.2009.310","article-title":"Lack of association between thiazolidinediones and macular edema in type 2 diabetes: the ACCORD eye substudy","volume":"128","author":"Ambrosius","year":"2010","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.survophthal.2025.01.010_bib5","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1167\/iovs.02-1060","article-title":"Role of PPAR-\u03b3 ligands in neuroprotection against glutamate-induced cytotoxicity in retinal ganglion cells","volume":"44","author":"Aoun","year":"2003","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.survophthal.2025.01.010_bib6","first-page":"110","article-title":"Experimental study of the effect of metformin on corneal burn ulcer healing in rabbit","volume":"29","author":"Asghari","year":"2016","journal-title":"Vet Res Biol Prod"},{"key":"10.1016\/j.survophthal.2025.01.010_bib7","doi-asserted-by":"crossref","DOI":"10.1590\/1414-431X20132818","article-title":"Effects of rosiglitazone on serum paraoxonase activity and metabolic parameters in patients with type 2 diabetes mellitus","author":"Atamer","year":"2013","journal-title":"Braz J Med Biol Res"},{"key":"10.1016\/j.survophthal.2025.01.010_bib8","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/dom.13538","article-title":"Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: a review","volume":"21","author":"Bain","year":"2019","journal-title":"Diabetes, Obes Metab"},{"key":"10.1016\/j.survophthal.2025.01.010_bib9","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/s41433-017-0003-1","article-title":"Cataract in patients with diabetes mellitus\u2014incidence rates in the UK and risk factors","volume":"32","author":"Becker","year":"2018","journal-title":"Eye"},{"key":"10.1016\/j.survophthal.2025.01.010_bib10","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.trsl.2020.10.003","article-title":"The antidiabetic drug glibenclamide exerts direct retinal neuroprotection","volume":"229","author":"Berdugo","year":"2021","journal-title":"Transl Res"},{"key":"10.1016\/j.survophthal.2025.01.010_bib11","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.3390\/pharmaceutics13071095","article-title":"Long-term oral treatment with non-hypoglycemic dose of glibenclamide reduces diabetic retinopathy damage in the goto-kakizakirat model","volume":"13","author":"Berdugo","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.survophthal.2025.01.010_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10020465","article-title":"Minimum effective dose of DPP-4 inhibitors for treating early stages of diabetic retinopathy in an experimental model","volume":"10","author":"Bogdanov","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.survophthal.2025.01.010_bib13","doi-asserted-by":"crossref","DOI":"10.1042\/CS20171299","article-title":"Cardiovascular benefits of GLP-1 agonists in type 2 diabetes: a comparative review","author":"Boyle","year":"2018","journal-title":"Clin Sci"},{"key":"10.1016\/j.survophthal.2025.01.010_bib14","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1464-5491.2008.02650.x","article-title":"A dramatic deterioration in diabetic retinopathy with improvement in glycated haemoglobin (HbA(1c)) on exenatide treatment","volume":"26","author":"Brooks","year":"2009","journal-title":"Diabet Med"},{"key":"10.1016\/j.survophthal.2025.01.010_bib15","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1177\/11206721231206790","article-title":"Topical insulin, a novel corneal epithelial regeneration agent in dry eye disease","volume":"34","author":"Burgos-Blasco","year":"2023","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.survophthal.2025.01.010_bib16","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0168-8227(93)90005-P","article-title":"The effect of acarbose on diabetes-and age-related basement membrane thickening in retinal capillaries of the BBW-rat","volume":"20","author":"Chakrabarti","year":"1993","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.survophthal.2025.01.010_bib17","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s12886-024-03436-3","article-title":"Insulin eye drops improve corneal wound healing in STZ-induced diabetic mice by regulating corneal inflammation and neuropeptide release","volume":"24","author":"Chen","year":"2024","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.survophthal.2025.01.010_bib18","doi-asserted-by":"crossref","DOI":"10.1002\/kjm2.12800","article-title":"Recent Advances in the Treatment of Type 2 Diabetes Mellitus Using New Drug Therapies","author":"Chong","year":"2024","journal-title":"Kaohsiung J Med Sci"},{"key":"10.1016\/j.survophthal.2025.01.010_bib19","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.exer.2016.04.020","article-title":"ATP sensitive potassium channel openers: a new class of ocular hypotensive agents","volume":"158","author":"Chowdhury","year":"2017","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.survophthal.2025.01.010_bib20","doi-asserted-by":"crossref","first-page":"540","DOI":"10.7150\/ijms.90273","article-title":"Prescription of glucagon-like peptide 1 agonists and risk of subsequent open-angle glaucoma in individuals with type 2 diabetes mellitus","volume":"21","author":"Chuang","year":"2024","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.survophthal.2025.01.010_bib21","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1079\/BJN19950165","article-title":"Aldose reductase (EC 1.1. 1.21) activity and reduced-glutathione content in lenses of diabetic sand rats (Psammomys obesus) fed with acarbose","volume":"74","author":"Cohen-Melamed","year":"1995","journal-title":"Br J Nutr"},{"key":"10.1016\/j.survophthal.2025.01.010_bib22","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"Group CTR: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","author":"Control","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.survophthal.2025.01.010_bib23","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/(SICI)1520-7560(199907\/08)15:4<289::AID-DMRR48>3.0.CO;2-V","article-title":"Effects of the alpha-glucosidase inhibitor acarbose on the development of long-term complications in diabetic animals: pathophysiological and therapeutic implications","volume":"15","author":"Creutzfeldt","year":"1999","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.survophthal.2025.01.010_bib24","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jama.2022.0078","article-title":"Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial","volume":"327","author":"Dahl","year":"2022","journal-title":"Jama"},{"key":"10.1016\/j.survophthal.2025.01.010_bib25","doi-asserted-by":"crossref","DOI":"10.3810\/pgm.2014.10.2819","article-title":"Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes","author":"Davidson","year":"2014","journal-title":"Postgrad Med"},{"key":"10.1016\/j.survophthal.2025.01.010_bib26","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.2337\/dc17-2280","article-title":"Glucagon-like peptide 1 receptor agonists and the risk of incident diabetic retinopathy","volume":"41","author":"Douros","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.survophthal.2025.01.010_bib27","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","author":"Drucker","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.survophthal.2025.01.010_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.tice.2022.101786","article-title":"Can metformin modulate the retinal degenerative changes in a rat model of retinitis pigmentosa?","volume":"76","author":"Eltony","year":"2022","journal-title":"Tissue Cell"},{"key":"10.1016\/j.survophthal.2025.01.010_bib29","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1007\/s00417-011-1903-6","article-title":"Rosiglitazone attenuates activation of human Tenon\u2019s fibroblasts induced by transforming growth factor-\u03b21","volume":"250","author":"Fan","year":"2012","journal-title":"Graefe'S Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.survophthal.2025.01.010_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2021.101280","article-title":"Dapagliflozin increases retinal thickness in type 2 diabetic patients as compared with glibenclamide: a randomized controlled trial","volume":"47","author":"Fernandes","year":"2021","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.survophthal.2025.01.010_bib31","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1161\/CIRCULATIONAHA.118.037778","article-title":"Empagliflozin reduced mortality and hospitalization for heart failure across the spectrum of cardiovascular risk in the EMPA-REG OUTCOME trial","volume":"139","author":"Fitchett","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.survophthal.2025.01.010_bib32","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.ajo.2008.10.016","article-title":"Glitazone use associated with diabetic macular edema","volume":"147","author":"Fong","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.survophthal.2025.01.010_bib33","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/635472","article-title":"Cardiovascular benefits of GLP-1-basedtherapies in patients with diabetes mellitus type 2: effects on endothelial and vascular dysfunction beyond glycemic control","author":"Forst","year":"2012","journal-title":"Exp Diabetes Res"},{"key":"10.1016\/j.survophthal.2025.01.010_bib34","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.survophthal.2025.01.010_bib35","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/ki.2013.427","article-title":"The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential","volume":"85","author":"Fujita","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.survophthal.2025.01.010_bib36","first-page":"356","article-title":"Effect of rapid glycemic control on progression of diabetic retinopathy","volume":"36","author":"Funatsu","year":"1992","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.survophthal.2025.01.010_bib37","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgz069","article-title":"Glucagon-like Peptide 1 receptor agonists, diabetic retinopathy and angiogenesis: the angiosafe type 2 diabetes study","volume":"105","author":"Gaborit","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.survophthal.2025.01.010_bib38","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/j.bbadis.2014.04.013","article-title":"Dipeptidyl peptidase-IV inhibition prevents blood\u2013retinal barrier breakdown, inflammation and neuronal cell death in the retina of type 1 diabetic rats","volume":"1842","author":"Gon\u00e7alves","year":"2014","journal-title":"Biochim Et Biophys Acta (BBA)-Mol Basis Dis"},{"key":"10.1016\/j.survophthal.2025.01.010_bib39","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/j.1463-1326.2011.01548.x","article-title":"Protective effects of the dipeptidyl peptidase IV inhibitor sitagliptin in the blood\u2013retinal barrier in a type 2 diabetes animal model","volume":"14","author":"Gon\u00e7alves","year":"2012","journal-title":"Diabetes, Obes Metab"},{"key":"10.1016\/j.survophthal.2025.01.010_bib40","doi-asserted-by":"crossref","DOI":"10.22270\/jddt.v9i4-s.3275","article-title":"Review on teneligliptin: a novel antihyperglycemic agent","author":"Gorde","year":"2019","journal-title":"J Drug Deliv Ther"},{"key":"10.1016\/j.survophthal.2025.01.010_bib41","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ajo.2017.12.007","article-title":"Lack of longitudinal association between thiazolidinediones and incidence and progression of diabetic eye disease: the ACCORD eye study","volume":"187","author":"Gower","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.survophthal.2025.01.010_bib42","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s12325-014-0101-4","article-title":"Pathophysiological and pharmacological rationale for the use of exenatide once weekly in patients with type 2 diabetes","volume":"31","author":"Grossman","year":"2014","journal-title":"Adv Ther"},{"key":"10.1016\/j.survophthal.2025.01.010_bib43","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.survophthal.2025.01.010_bib44","doi-asserted-by":"crossref","first-page":"18856","DOI":"10.1074\/jbc.M110.179317","article-title":"Peroxisome proliferator-activated receptor \u03b3 ligands inhibit transforming growth factor-\u03b2-induced, hyaluronan-dependent, T cell adhesion to orbital fibroblasts","volume":"286","author":"Guo","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.survophthal.2025.01.010_bib45","first-page":"53","article-title":"Influence of diabetes mellitus on anterior segment of the eye","author":"Han","year":"2019","journal-title":"Clin Interv Aging"},{"key":"10.1016\/j.survophthal.2025.01.010_bib46","doi-asserted-by":"crossref","first-page":"6955","DOI":"10.1167\/iovs.12-10488","article-title":"Epithelial-mesenchymal transition-like phenotypic changes of retinal pigment epithelium induced by TGF-\u03b2 are prevented by PPAR-\u03b3 agonists","volume":"53","author":"Hatanaka","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.survophthal.2025.01.010_bib47","doi-asserted-by":"crossref","DOI":"10.1001\/jamaophthalmol.2024.2296","article-title":"Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide","author":"Hathaway","year":"2024","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.survophthal.2025.01.010_bib48","article-title":"Topical administration of GLP-1 receptor agonists prevents retinal neurodegeneration in experimental diabetes","author":"Hern\u00e1ndez","year":"2015","journal-title":"Diabetes"},{"key":"10.1016\/j.survophthal.2025.01.010_bib49","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/dmrr.1093","article-title":"Effect of intensive insulin therapy on macular biometrics, plasma VEGF and its soluble receptor in newly diagnosed diabetic patients","volume":"26","author":"Hern\u00e1ndez","year":"2010","journal-title":"Diabetes\/Metab Res Rev"},{"key":"10.1016\/j.survophthal.2025.01.010_bib50","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1001\/jamaophthalmol.2016.5318","article-title":"Association of systemic medication use with intraocular pressure in a multiethnic asian population: the singapore epidemiology of eye diseases study","volume":"135","author":"Ho","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.survophthal.2025.01.010_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.fct.2020.111738","article-title":"An overview on the role of bioactive \u03b1-glucosidase inhibitors in ameliorating diabetic complications","author":"Hossain","year":"2020","journal-title":"Food Chem Toxicol"},{"key":"10.1016\/j.survophthal.2025.01.010_bib52","doi-asserted-by":"crossref","DOI":"10.2337\/dc16-0346","article-title":"Do mobile phone applications improve glycemic control (HbA1c) in the self-management of diabetes? A systematic review, meta-analysis, and GRADE of 14 randomized trials","author":"Hou","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.survophthal.2025.01.010_bib53","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.3390\/cells10082131","article-title":"Metformin and glaucoma\u2014review of anti-fibrotic processes and bioenergetics","volume":"10","author":"Hurley","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.survophthal.2025.01.010_bib54","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.survophthal.2025.01.010_bib55","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1001\/archinternmed.2012.1938","article-title":"Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes","volume":"172","author":"Idris","year":"2012","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.survophthal.2025.01.010_bib56","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/dom.15367","article-title":"Incretin-based drugs and the risk of diabetic retinopathy among individuals with type 2 diabetes: a systematic review and meta-analysis of observational studies","volume":"26","author":"Igweokpala","year":"2024","journal-title":"Diabetes, Obes Metab"},{"key":"10.1016\/j.survophthal.2025.01.010_bib57","doi-asserted-by":"crossref","unstructured":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). The Lancet; 1998 352 p.837-853, .","DOI":"10.1016\/S0140-6736(98)07019-6"},{"key":"10.1016\/j.survophthal.2025.01.010_bib58","article-title":"Composite retinopathy outcome in patients treated with empagliflozin versus placebo in the EMPA-REG OUTCOME trial","volume":"14","author":"Inzucchi","year":"2019","journal-title":"Diabetol und Stoffwechs"},{"key":"10.1016\/j.survophthal.2025.01.010_bib59","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.2174\/1381612821666150710145753","article-title":"Antidiabetic drugs: mechanisms of action and potential outcomes on cellular metabolism","volume":"21","author":"J Meneses","year":"2015","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.survophthal.2025.01.010_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12902-017-0213-3","article-title":"Mechanism of worsening diabetic retinopathy with rapid lowering of blood glucose: the synergistic hypothesis","volume":"17","author":"Jingi","year":"2017","journal-title":"BMC Endocr Disord"},{"key":"10.1016\/j.survophthal.2025.01.010_bib61","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1016\/j.bbadis.2015.09.010","article-title":"Gemigliptin, a dipeptidyl peptidase-4 inhibitor, inhibits retinal pericyte injury in db\/db mice and retinal neovascularization in mice with ischemic retinopathy","volume":"1852","author":"Jung","year":"2015","journal-title":"Biochim Et Biophys Acta (BBA) - Mol Basis Dis"},{"key":"10.1016\/j.survophthal.2025.01.010_bib62","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1167\/iovs.12-9432","article-title":"Antidiabetic drug metformin suppresses endotoxin-induced uveitis in rats","volume":"53","author":"Kalariya","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.survophthal.2025.01.010_bib63","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.survophthal.2023.07.002","article-title":"GLP-1 receptor agonists and diabetic retinopathy: a meta-analysis of randomized clinical trials","volume":"68","author":"Kapoor","year":"2023","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.survophthal.2025.01.010_bib64","article-title":"Association of metformin use with risk of newly onset neovascular age-related macular degeneration development","volume":"44","author":"Khanna","year":"2024","journal-title":"RETINA"},{"key":"10.1016\/j.survophthal.2025.01.010_bib65","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.diabet.2018.03.004","article-title":"Dipeptidyl peptidase-4 inhibitor use and risk of diabetic retinopathy: a population-based study","volume":"44","author":"Kim","year":"2018","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.survophthal.2025.01.010_bib66","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s00125-002-0820-y","article-title":"Effective and selective prevention of retinal leukostasis in streptozotocin-induced diabetic rats using gliclazide","volume":"45","author":"Kinoshita","year":"2002","journal-title":"Diabetologia"},{"key":"10.1016\/j.survophthal.2025.01.010_bib67","first-page":"574","article-title":"Long-term, topical insulin administration increases the severity of retinal vascular pathology in streptozotocin-induced diabetic rats","volume":"78","author":"Koevary","year":"2007","journal-title":"Optom - J Am Optom Assoc"},{"key":"10.1016\/j.survophthal.2025.01.010_bib68","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1007\/s00125-018-4701-4","article-title":"Anti-angiogenic effects of the DPP-4 inhibitor linagliptin via inhibition of VEGFR signalling in the mouse model of oxygen-induced retinopathy","volume":"61","author":"Kolibabka","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.survophthal.2025.01.010_bib69","doi-asserted-by":"crossref","DOI":"10.2147\/OPTH.S301317","article-title":"Management of patients with newly diagnosed diabetic mellitus: ophthalmologic outcomes in intensive versus conventional glycemic control","author":"Lam","year":"2021","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.survophthal.2025.01.010_bib70","doi-asserted-by":"crossref","DOI":"10.2337\/db07-1202","article-title":"Differential antidiabetic efficacy of incretin agonists versus DPP-4 inhibition in high fat\u2013fed mice","author":"Lamont","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.survophthal.2025.01.010_bib71","article-title":"Dipeptidyl peptidase-4 inhibitor increases vascular leakage in retina through VE-cadherin phosphorylation","volume":"6","author":"Lee","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.survophthal.2025.01.010_bib72","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.2337\/dc20-3133","article-title":"Sodium\u2013glucose cotransporter 2 inhibitors and risk of retinal vein occlusion among patients with type 2 diabetes: a propensity score\u2013matched cohort study","volume":"44","author":"Lee","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.survophthal.2025.01.010_bib73","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/dom.14197","article-title":"Sodium-glucose co-transporter-2 inhibition and ocular outcomes in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"23","author":"Li","year":"2021","journal-title":"Diabetes, Obes Metab"},{"key":"10.1016\/j.survophthal.2025.01.010_bib74","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.intimp.2018.10.040","article-title":"Vascular protection of DPP-4 inhibitors in retinal endothelial cells in in vitro culture","volume":"66","author":"Li","year":"2019","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.survophthal.2025.01.010_bib75","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.3389\/fphar.2020.01038","article-title":"Eye drops of metformin prevents fibrosis after glaucoma filtration surgery in rats via activating AMPK\/Nrf2 signaling pathway","volume":"11","author":"Li","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.survophthal.2025.01.010_bib76","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1001\/jamaophthalmol.2015.1440","article-title":"Association of geroprotective effects of metformin and risk of open-angle glaucoma in persons with diabetes mellitus","volume":"133","author":"Lin","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.survophthal.2025.01.010_bib77","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0188136","article-title":"Protective effect of metformin against retinal vein occlusions in diabetes mellitus\u2013a nationwide population-based study","volume":"12","author":"Lin","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.survophthal.2025.01.010_bib78","doi-asserted-by":"crossref","first-page":"394","DOI":"10.4093\/dmj.2022.0221","article-title":"Risk of diabetic retinopathy between sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists","volume":"47","author":"Lin","year":"2023","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.survophthal.2025.01.010_bib79","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.3773","article-title":"Association of sodium-glucose cotransporter-2 inhibitors and the risk of retinal vascular occlusion: a real-world retrospective cohort study in Taiwan","volume":"40","author":"Lin","year":"2024","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.survophthal.2025.01.010_bib80","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","article-title":"Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial","volume":"398","author":"Ludvik","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.survophthal.2025.01.010_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2017.12.008","article-title":"Incretin-based therapy for the treatment of bone fragility in diabetes mellitus","author":"Mabilleau","year":"2018","journal-title":"Peptides"},{"key":"10.1016\/j.survophthal.2025.01.010_bib82","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.survophthal.2025.01.010_bib83","article-title":"Ocular cicatricial pemphigoid following Dipeptidyl Peptidase-4 inhibitor use: a case report","volume":"32","author":"Matsumoto","year":"2023","journal-title":"Am J Ophthalmol Case Rep"},{"key":"10.1016\/j.survophthal.2025.01.010_bib84","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1089\/105072503322401032","article-title":"Peroxisome proliferator-activated receptor-\u03b3 gene expression in orbital adipose\/connective tissues is increased during the active stage of graves' ophthalmopathy","volume":"13","author":"Mimura","year":"2003","journal-title":"Thyroid"},{"key":"10.1016\/j.survophthal.2025.01.010_bib85","article-title":"The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: the SURPASS clinical trials","author":"Min","year":"2020","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.survophthal.2025.01.010_bib86","doi-asserted-by":"crossref","first-page":"11184","DOI":"10.3390\/ijms231911184","article-title":"Assessment of efficacy and safety using PPAR-\u03b3 agonist-loaded nanocarriers for inflammatory eye diseases","volume":"23","author":"Miralles","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.survophthal.2025.01.010_bib87","doi-asserted-by":"crossref","DOI":"10.18203\/2319-2003.ijbcp20191125","article-title":"Clinical challenges with excipients in insulin formulations and role of concentrated insulin","author":"Modi","year":"2019","journal-title":"Int J Basic Clin Pharmacol"},{"key":"10.1016\/j.survophthal.2025.01.010_bib88","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s12020-009-9208-9","article-title":"Influence of insulin treatment on the lacrimal gland and ocular surface of diabetic rats","volume":"36","author":"M\u00f3dulo","year":"2009","journal-title":"Endocrine"},{"key":"10.1016\/j.survophthal.2025.01.010_bib89","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1167\/iovs.65.3.23","article-title":"The Association between metformin use and new-onset ICD coding of geographic atrophy","volume":"65","author":"Moir","year":"2024","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.survophthal.2025.01.010_bib90","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2165\/11596510-000000000-00000","article-title":"Cardiovascular, ocular and bone adverse reactions associated with thiazolidinediones: a disproportionality analysis of the US FDA adverse event reporting system database","volume":"35","author":"Motola","year":"2012","journal-title":"Drug Saf"},{"key":"10.1016\/j.survophthal.2025.01.010_bib91","doi-asserted-by":"crossref","first-page":"860","DOI":"10.18240\/ijo.2020.06.02","article-title":"PPAR\u03b3: the dominant regulator among PPARs in dry eye lacrimal gland and diabetic lacrimal gland","volume":"13","author":"Mu","year":"2020","journal-title":"Int J Ophthalmol"},{"key":"10.1016\/j.survophthal.2025.01.010_bib92","doi-asserted-by":"crossref","first-page":"5093","DOI":"10.3390\/ijms21145093","article-title":"Combination of peroxisome proliferator-activated receptor (PPAR) alpha and gamma agonists prevents corneal inflammation and neovascularization in a rat alkali burn model","volume":"21","author":"Nakano","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.survophthal.2025.01.010_bib93","series-title":"S. A research study to look at how semaglutide compared to placebo affects diabetic eye disease in people with type 2 diabetes (FOCUS);[about 9 screens]. ClinicalTrials. gov","author":"Novo Nordisk","year":"2000"},{"key":"10.1016\/j.survophthal.2025.01.010_bib94","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1007\/s00592-023-02135-7","article-title":"The effect of GLP-1 receptor agonist lixisenatide on experimental diabetic retinopathy","volume":"60","author":"Oezer","year":"2023","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.survophthal.2025.01.010_bib95","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.exer.2013.09.017","article-title":"Peroxisome proliferator-activated receptor-\u03b3 agonist pioglitazone suppresses experimental autoimmune uveitis","volume":"116","author":"Okunuki","year":"2013","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.survophthal.2025.01.010_bib96","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.peptides.2017.08.003","article-title":"The potential benefits of glucagon-like peptide-1 receptor agonists for diabetic retinopathy","volume":"100","author":"Pang","year":"2018","journal-title":"Peptides"},{"key":"10.1016\/j.survophthal.2025.01.010_bib97","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1172\/JCI0215634","article-title":"PPAR\u03b3 ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis","volume":"110","author":"Panigrahy","year":"2002","journal-title":"J Clin Investig"},{"key":"10.1016\/j.survophthal.2025.01.010_bib98","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1167\/iovs.62.10.24","article-title":"The protective effect of metformin use on early Nd: YAG laser capsulotomy","volume":"62","author":"Patnaik","year":"2021","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.survophthal.2025.01.010_bib99","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0002-9394(88)90190-0","article-title":"Systemic factors affecting diabetic macular edema","volume":"105","author":"Perkovich","year":"1988","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.survophthal.2025.01.010_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2022.111611","article-title":"Insulin facilitates corneal wound healing in the diabetic environment through the RTK-PI3K\/Akt\/mTOR axis in vitro","volume":"548","author":"Peterson","year":"2022","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.survophthal.2025.01.010_bib101","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1001\/archopht.118.1.55","article-title":"Effects of insulin on retinal and pulsatile choroidal blood flow in humans","volume":"118","author":"Polak","year":"2000","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.survophthal.2025.01.010_bib102","article-title":"Harnessing silk fibroin microparticles for metformin delivery: a novel approach to treating corneal neovascularization","volume":"96","author":"Polat","year":"2024","journal-title":"J Drug Deliv Sci Technol"},{"key":"10.1016\/j.survophthal.2025.01.010_bib103","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1172\/JCI0213776","article-title":"Acute intensive insulin therapy exacerbates diabetic blood-retinal barrier breakdown via hypoxia-inducible factor-1\u03b1 and VEGF","volume":"109","author":"Poulaki","year":"2002","journal-title":"J Clin Investig"},{"key":"10.1016\/j.survophthal.2025.01.010_bib104","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/975032","article-title":"Retinal pigment epithelial cells express a functional receptor for glucagon-like peptide-1 (GLP-1)","volume":"2013","author":"Puddu","year":"2013","journal-title":"Mediat Inflamm"},{"key":"10.1016\/j.survophthal.2025.01.010_bib105","doi-asserted-by":"crossref","DOI":"10.1186\/s12902-022-01036-0","article-title":"Glucagon-Like Peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of double-blind, randomized, placebo-controlled clinical trials","author":"Qin","year":"2022","journal-title":"BMC Endocr Disord"},{"key":"10.1016\/j.survophthal.2025.01.010_bib106","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9121772","article-title":"Neuromodulation Induced by sitagliptin: a new strategy for treating diabetic retinopathy","volume":"9","author":"Ramos","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.survophthal.2025.01.010_bib107","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24010571","article-title":"Transcriptomic analysis reveals that retinal neuromodulation is a relevant mechanism in the neuroprotective effect of sitagliptin in an experimental model of diabetic retinopathy","volume":"24","author":"Ramos","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.survophthal.2025.01.010_bib108","doi-asserted-by":"crossref","DOI":"10.1007\/s00204-016-1737-4","article-title":"The current role of thiazolidinediones in diabetes management","author":"Rizos","year":"2016","journal-title":"Arch Toxicol"},{"key":"10.1016\/j.survophthal.2025.01.010_bib109","first-page":"963","article-title":"Identification of insulin in the tear film and insulin receptor and IGF-I receptor on the human ocular surface","volume":"43","author":"Rocha","year":"2002","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.survophthal.2025.01.010_bib110","article-title":"Biochemical study on the hypoglycemic effects of extracted phenolic compounds from grape seeds in streptozotocin -induced diabetic rats","author":"Sarhat","year":"2021","journal-title":"Indian J Forensic Med Toxicol"},{"key":"10.1016\/j.survophthal.2025.01.010_bib111","doi-asserted-by":"crossref","DOI":"10.1038\/s41433-019-0494-z","article-title":"New anti-hyperglycaemic agents for type 2 diabetes and their effects on diabetic retinopathy","author":"Saw","year":"2019","journal-title":"Eye"},{"key":"10.1016\/j.survophthal.2025.01.010_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2011.11.001","article-title":"DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials","author":"Scheen","year":"2012","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.survophthal.2025.01.010_bib113","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.1114","article-title":"Efficacy and Safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus","author":"Scheen","year":"2010","journal-title":"Diabetes\/Metab Res Rev"},{"key":"10.1016\/j.survophthal.2025.01.010_bib114","doi-asserted-by":"crossref","DOI":"10.1038\/s12276-020-00512-8","article-title":"Evogliptin, a dipeptidyl peptidase-4 inhibitor, attenuates pathological retinal angiogenesis by suppressing vascular endothelial growth factor-induced Arf6 activation","author":"Seo","year":"2020","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.survophthal.2025.01.010_bib115","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1089\/jop.2019.0070","article-title":"Effect of insulin therapy on ocular biometric parameters in diabetic patients","volume":"36","author":"Seven","year":"2019","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.survophthal.2025.01.010_bib116","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3109\/13814788.2011.590191","article-title":"Is Rosiglitazone use associated with an increase in intensive eye treatment in diabetic patients? A community based study","volume":"17","author":"Shani","year":"2011","journal-title":"Eur J Gen Pract"},{"key":"10.1016\/j.survophthal.2025.01.010_bib117","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2022.101318","article-title":"Association between sodium glucose co-transporter 2 inhibitors and incident glaucoma in patients with type 2 diabetes: a multi-institutional cohort study in Taiwan","volume":"48","author":"Shao","year":"2022","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.survophthal.2025.01.010_bib118","first-page":"1","article-title":"Association of metformin treatment with enhanced effect of anti-VEGF agents in diabetic macular edema patients","author":"Shao","year":"2022","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.survophthal.2025.01.010_bib119","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1001\/archopht.126.6.793","article-title":"Rosiglitazone and delayed onset of proliferative diabetic retinopathy","volume":"126","author":"Shen","year":"2008","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.survophthal.2025.01.010_bib120","doi-asserted-by":"crossref","DOI":"10.5114\/aoms.2015.53304","article-title":"State of the art paper sulfonylureas and their use in clinical practice","author":"Sola","year":"2015","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.survophthal.2025.01.010_bib121","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1210\/jc.2002-020987","article-title":"Peroxisome proliferator-activated receptor-\u03b3 in thyroid eye disease: contraindication for thiazolidinedione use?","volume":"88","author":"Starkey","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.survophthal.2025.01.010_bib122","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1136\/bjophthalmol-2021-319232","article-title":"Glucagon-like peptide 1 receptor agonist use is associated with reduced risk for glaucoma","volume":"107","author":"Sterling","year":"2023","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.survophthal.2025.01.010_bib123","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.32584","article-title":"Comparison of sodium-glucose cotransporter 2 inhibitors vs glucagonlike peptide-1 receptor agonists and incidence of dry eye disease in patients with type 2 diabetes in Taiwan","volume":"5","author":"Su","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.survophthal.2025.01.010_bib124","unstructured":"SureVision: Ozempic Use and Worsening Diabetic Retinopathy: SureVision, Vol. 2024, 2024."},{"key":"10.1016\/j.survophthal.2025.01.010_bib125","doi-asserted-by":"crossref","DOI":"10.26911\/thejhpm.2022.07.02.03","article-title":"Meta-analysis the effect of pharmaceutical care on blood glucose level in type 2 diabetes mellitus patients","author":"Syafira","year":"2022","journal-title":"J Health Policy Manag"},{"key":"10.1016\/j.survophthal.2025.01.010_bib126","doi-asserted-by":"crossref","first-page":"741","DOI":"10.3109\/02713689508995795","article-title":"Reversal of abnormal retinal hemodynamics in diabetic rats by acarbose, an \u03b1-glucosidase inhibitor","volume":"14","author":"Takagi","year":"1995","journal-title":"Curr eye Res"},{"key":"10.1016\/j.survophthal.2025.01.010_bib127","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.lfs.2016.01.042","article-title":"Effect of ipragliflozin, an SGLT2 inhibitor, on progression of diabetic microvascular complications in spontaneously diabetic Torii fatty rats","volume":"147","author":"Takakura","year":"2016","journal-title":"Life Sci"},{"key":"10.1016\/j.survophthal.2025.01.010_bib128","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1111\/dom.13232","article-title":"Comparisons of diabetic retinopathy events associated with glucose-lowering drugs in patients with type 2 diabetes mellitus: a network meta-analysis","volume":"20","author":"Tang","year":"2018","journal-title":"Diabetes, Obes Metab"},{"key":"10.1016\/j.survophthal.2025.01.010_bib129","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01238","article-title":"Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid","volume":"10","author":"Tasanen","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.survophthal.2025.01.010_bib130","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.ophtha.2021.04.027","article-title":"Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and meta-analysis","volume":"128","author":"Teo","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2025.01.010_bib131","doi-asserted-by":"crossref","DOI":"10.3390\/ph15030312","article-title":"Metformin: a narrative review of its potential benefits for cardiovascular disease, cancer and dementia","author":"Top","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.survophthal.2025.01.010_bib132","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.lfs.2017.09.008","article-title":"PPAR\u03b3 agonists: Potential treatments for exudative age-related macular degeneration","volume":"188","author":"Vall\u00e9e","year":"2017","journal-title":"Life Sci"},{"key":"10.1016\/j.survophthal.2025.01.010_bib133","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1016\/j.diabres.2013.12.041","article-title":"The impact of improved glycaemic control with GLP-1 receptor agonist therapy on diabetic retinopathy","volume":"103","author":"Varadhan","year":"2014","journal-title":"Diabetes Res Clin Pr"},{"key":"10.1016\/j.survophthal.2025.01.010_bib134","article-title":"Impact of GLP-1 Agonists and SGLT-2 inhibitors on diabetic retinopathy progression: an aggregated electronic health record data study","author":"Wai","year":"2024","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.survophthal.2025.01.010_bib135","doi-asserted-by":"crossref","DOI":"10.1093\/glycob\/cwx047","article-title":"Sodium glucose cotransporter 2 in mesangial cells and retinal pericytes and its implications for diabetic nephropathy and retinopathy","author":"Wakisaka","year":"2017","journal-title":"Glycobiology"},{"key":"10.1016\/j.survophthal.2025.01.010_bib136","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2023.5573","article-title":"GLP-1 receptor agonists and colorectal cancer risk in drug-naive patients with type 2 diabetes, with and without overweight\/obesity","author":"Wang","year":"2024","journal-title":"Jama Oncol"},{"key":"10.1016\/j.survophthal.2025.01.010_bib137","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.survophthal.2025.01.010_bib138","article-title":"Curcumin and metformin synergistically modulate peripheral and central immune mechanisms of pain","author":"Wasana","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.survophthal.2025.01.010_bib139","doi-asserted-by":"crossref","DOI":"10.4103\/2230-8210.81947","article-title":"Metformin high dosage and bleeding episode: a clinical case study","author":"Wiwanitkit","year":"2011","journal-title":"Indian J Endocrinol Metab"},{"key":"10.1016\/j.survophthal.2025.01.010_bib140","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.609110","article-title":"Glucagon-like peptide-1 receptor agonists for non-alcoholic fatty liver disease in type 2 diabetes: a meta-analysis","volume":"12","author":"Wong","year":"2021","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.survophthal.2025.01.010_bib141","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.ophtha.2020.12.027","article-title":"OCT angiography for the diagnosis of glaucoma: a report by the American Academy of Ophthalmology","volume":"128","author":"WuDunn","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2025.01.010_bib142","first-page":"143","article-title":"Troglitazone induced apoptosis of human pterygium fibroblasts through a mitochondrial-dependent pathway","volume":"4","author":"Yang","year":"2011","journal-title":"Int J Ophthalmol"},{"key":"10.1016\/j.survophthal.2025.01.010_bib143","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1089\/jop.2000.16.471","article-title":"Acarbose partially inhibits microvascular retinopathy in the zucker diabetic fatty rat (ZDF\/GmiTM-fa)","volume":"16","author":"Yang","year":"2000","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.survophthal.2025.01.010_bib144","first-page":"541","article-title":"Effects of glibornuride versus metformin on eye lenses and skin in experimental diabetes","volume":"56","author":"Yarat","year":"2006","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.survophthal.2025.01.010_bib145","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2019.116776","article-title":"Molecular Mechanisms by Which GLP-1 RA and DPP-4i Induce Insulin Sensitivity","author":"Yaribeygi","year":"2019","journal-title":"Life Sci"},{"key":"10.1016\/j.survophthal.2025.01.010_bib146","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1167\/iovs.64.10.2","article-title":"DPP-4 inhibitors attenuate fibrosis after glaucoma filtering surgery by suppressing the TGF-\u03b2\/Smad signaling pathway","volume":"64","author":"Yoshida","year":"2023","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.survophthal.2025.01.010_bib147","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2022.108255","article-title":"Progression of retinopathy with glucagon-like peptide-1 receptor agonists with cardiovascular benefits in type 2 diabetes \u2013 A systematic review and meta-analysis","volume":"36","author":"Yoshida","year":"2022","journal-title":"J Diabetes its Complicat"},{"key":"10.1016\/j.survophthal.2025.01.010_bib148","doi-asserted-by":"crossref","DOI":"10.12659\/AJCR.909708","article-title":"Recovery from diabetic macular edema in a diabetic patient after minimal dose of a sodium glucose co-transporter 2 inhibitor","author":"Yoshizumi","year":"2018","journal-title":"Am J Case Rep"},{"key":"10.1016\/j.survophthal.2025.01.010_bib149","article-title":"Metformin: a unique herbal origin medication","volume":"17","author":"Yousef","year":"2017","journal-title":"Glob J Med Res"},{"key":"10.1016\/j.survophthal.2025.01.010_bib150","doi-asserted-by":"crossref","first-page":"136","DOI":"10.23876\/j.krcp.22.001","article-title":"GLP-1 receptor agonists in diabetic kidney disease: current evidence and future directions","volume":"41","author":"Yu","year":"2022","journal-title":"Kidney Res Clin Pract"},{"key":"10.1016\/j.survophthal.2025.01.010_bib151","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3390\/biom12020281","article-title":"Systemic treatment with pioglitazone reverses vision loss in preclinical glaucoma models","volume":"12","author":"Zeng","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.survophthal.2025.01.010_bib152","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1111\/bph.15059","article-title":"Exendin-4, a GLP-1 receptor agonist regulates retinal capillary tone and restores microvascular patency after ischaemia\u2013reperfusion injury","volume":"177","author":"Zhai","year":"2020","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.survophthal.2025.01.010_bib153","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/275435","article-title":"Role of peroxisome proliferator-activated receptor \u03b3 in ocular diseases","volume":"2015","author":"Zhang","year":"2015","journal-title":"J Ophthalmol"},{"key":"10.1016\/j.survophthal.2025.01.010_bib154","article-title":"Relationship between SGLT-2i and ocular diseases in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials","volume":"13","author":"Zhou","year":"2022","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.survophthal.2025.01.010_bib155","article-title":"Diabetes mellitus as a risk factor for open-angle glaucoma: a systematic review and meta-analysis","volume":"9","author":"Zhou","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.survophthal.2025.01.010_bib156","doi-asserted-by":"crossref","DOI":"10.1016\/S0889-8529(05)70264-4","article-title":"Sulfonylureas","author":"Zimmerman","year":"1997","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.survophthal.2025.01.010_bib157","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","author":"Zinman","year":"2015","journal-title":"N Engl J Med"}],"container-title":["Survey of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625725000190?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625725000190?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T09:28:12Z","timestamp":1747474092000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039625725000190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":157,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S0039625725000190"],"URL":"https:\/\/doi.org\/10.1016\/j.survophthal.2025.01.010","relation":{},"ISSN":["0039-6257"],"issn-type":[{"value":"0039-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An update on ocular effects of antidiabetic medications","name":"articletitle","label":"Article Title"},{"value":"Survey of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.survophthal.2025.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}